Showing results (831-840 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
The Lancet. Oncology|June 17, 2026
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre studyKevin B W Groot Lipman, Rianne Wittenberg, Mateus de Oliveira Taveira, et al.
The Lancet. Oncology|July 1, 2026
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trialHuabin Hu, Xutao Shen, Yunfeng Li, et al.
The Lancet. Oncology|July 3, 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trialLeonardo Brunetti, Valentina Santo, David J Pinato, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
The Lancet. Oncology|July 13, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trialMing Gao, Young Joo Park, Chia-Chi Lin, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
The Lancet. Oncology|July 27, 2026
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trialMark D Tyson, Jong-Kil Nam, Shreyas S Joshi, et al.
The Lancet. Oncology|August 24, 2026
Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trialRafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, et al.
The Lancet. Oncology|August 24, 2026
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation studyJulia R Dixon-Douglas, Damien Drubay, Roberto Salgado, et al.
Pageof 338